Pilot clinical evaluation of Al18F-PSMA-BCH for primaryprostate cancer

Conclusions: Al18F-PSMA-BCH was safe with proper effective absorbed dosimetry. It showed good detecting ability of tumor lesions and detected more tumor lesions than 11C-choline. The pilot clinical study showed Al18F-PSMA-BCH was potential for clinical application. Keywords Al18F PSMA-BCH, PET imaging, radiation dosimetry References Siegel RL, Miller KD, Jemal A. CA cancer J Clin. 2017;67:7-30.Rowe SP, Drzezga A, Neumaier B, et al. J Nucl Med. 2016;57:90S-96S.Afshar-Oromieh A, Babich J, Kratochwil C, et al. J Nucl Med. 2016;57:79S-89S.Dietlein M, Kobe C, Kuhnert G, et al. Mol Imaging Biol. 2015;17:575-584.Dietlein F, Kobe C, Neubauer S, et al. J Nucl Med. 2017;58:947-952.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Oncology, Basic and Translational - PSMA based agents Source Type: research